American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

NCT ID: NCT02674100

Last Updated: 2025-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.

The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

The rationale for creating this multi-center clinical database is to optimally collect clinical and pathological data on patients with neoplasms in order to facilitate future clinical observational and outcomes-based research.

Inclusion Criteria

Patients will be considered eligible for inclusion into the database if they meet the following eligibility criteria:

Evidence/suspicion of Pancreatic neoplasm ≥ 18 years of age

Exclusion Criteria Patients will be considered ineligible for inclusion into the database if they are not able to give consent.

Inclusion of Women, Minorities and Vulnerable Subjects This protocol will include women and minority populations. Vulnerable subjects (prisoners, children, mentally disabled persons) will not be included in the study population.

Primary Study Objective(s):

To provide insight in treatment selection and treatment outcome of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with Pancreatic cancer requiring surgical intervention.

Secondary Study Objective(s):

To provide data on adverse events and complications related to IRE treatment.

The AHPBA will be responsible for data collection and will periodically audit the data for quality assurance purposes. The AHPBA will review outcomes reported by each participating Research Institution and if outcomes are in the lower percentile, the investigators will be offered support to analyze the reasons for the suboptimal outcomes and may seek support to improve outcomes. The participating Research Institutions will receive a certificate annually that acknowledges their participation in the Research Project.

Goal and Aims of Registry?

The Specific Aims are:

* Gain a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors
* Understand the limitations, concerns, and complications that earlier users of ablation in the treatment of unresectable soft tissue pancreatic tumors have

Create a multi-institutional group that will both enroll in this registry study, but more importantly enroll in future, prospective ablation in the treatments of unresectable soft tissue pancreatic tumors studies. Any patient undergoing a soft tissue ablation may be included in this study. To confirm, you will always own your data and the registry will be used as data storage until you release your data for evaluation on a project-by-project basis.

What Patients are Eligible?

• Any patient to which the treating physician believes that ablation of their soft tissue would be feasible in the care of their disease.

Patients who can be followed and can provide outcome data to achieve the Goals and Aims of the Registry.

To participate, the only thing we need to obtain from your site is a regulatory approval letter stating that it is acceptable to collaborate with your patients de-identified data (sample data collection protocol is attached) and that you will be consenting your patients to this data collaboration (The Registry).

Case report forms/ data collection sheets are attached The data entry will be web based. All treatments must be entered-not just the first treatment. All follow up-up to 2 years or until death of patient-must be entered. Common follow up is every 3-4 months for first year and every 6 months for second year. In order to ensure data accuracy we require that, for the first 5 patients entered, the data sheets and their supporting documentation (de-identified labs, treatment dictation, etc.) be sent to us so we can make sure the data entry is correct and complete (e.g., lesion dimensions, measures of response or progression, etc.).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Registry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.

Exclusion Criteria

* Have a cardiac pacemaker or ICD implant
* Non-removable implants with metal parts near target lesion
* Myocardial infarction within 3 months prior to enrollment
* Not suitable for general endotracheal anesthesia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Americas Hepato-Pancreato-Biliary Association

UNKNOWN

Sponsor Role collaborator

University of Louisville

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert C. Martin

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Martin, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Louisville

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama Birmingham

Birmingham, Alabama, United States

Site Status RECRUITING

University of California San Diego

San Diego, California, United States

Site Status RECRUITING

University of Colorado

Denver, Colorado, United States

Site Status RECRUITING

University of South Florida

Tampa, Florida, United States

Site Status RECRUITING

Augusta University

Augusta, Georgia, United States

Site Status RECRUITING

University of Louisville

Louisville, Kentucky, United States

Site Status RECRUITING

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status RECRUITING

Atlantic Health

Millburn, New Jersey, United States

Site Status RECRUITING

Northwell Health Cancer Institute

Lake Success, New York, United States

Site Status RECRUITING

Gibbs Cancer Research, Spartanburg Regional Healthcare System

Spartanburg, South Carolina, United States

Site Status RECRUITING

Methodist Digestive Institute

Dallas, Texas, United States

Site Status RECRUITING

McGill University

Montreal, Quebec, Canada

Site Status RECRUITING

Sanno Hospital

Tokyo, Japan, Japan

Site Status RECRUITING

Centro Medico

Mexico City, , Mexico

Site Status RECRUITING

National Taiwan University

Taipei, , Taiwan

Site Status RECRUITING

Freeman Hospital

High Heaton, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Japan Mexico Taiwan United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Robert Martin, MD, PhD

Role: CONTACT

502-629-3355

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

John Christein, MD

Role: primary

Rebekah White, MD

Role: primary

Ana Gleisner

Role: primary

Rachel Karlnoski

Role: primary

Edward Kruse, MD

Role: primary

Matthew Weiss, MD

Role: primary

Kai Bickenbach, MD

Role: primary

Gary Deutsch, MD

Role: primary

Heather Farmer

Role: primary

Alejandro Mejia, MD

Role: primary

Yifan Wang

Role: primary

Morivasu Fuminori, MD

Role: primary

Carlos Florez-Zorrilla, MD

Role: primary

Huang Kai-Wen, MD

Role: primary

Derek Manas, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-326

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mesopancreas Study in Pancreatic Cancer
NCT05895214 NOT_YET_RECRUITING
PROMs After Pancreatectomy
NCT07173257 RECRUITING